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Summary
The gene hypermethylated in cancer 1 (HIC1) is epigenetically inactivated, but not mutated, in cancer. Here we show that
cooperative loss of Hic1 with p53, but not INK4a, yields distinct tumor phenotypes in mice. Germline deletion of one allele
of each gene on the opposite chromosome yields breast and ovarian carcinomas and metastatic osteosarcomas with
epigenetic inactivation of the wild-type Hic1 allele. Germline deletion of the two genes on the same chromosome results
in earlier appearance and increased prevalence and aggressiveness of osteosarcomas with genetic deletion of both wild-
type genes. In human osteosarcomas, hypermethylation of HIC1 is frequent only in tumors with p53 mutations. Our results
indicate the importance of genes altered only through epigenetic mechanisms in cancer progression in conjunction with
genetically modified tumor suppressor genes.
Introduction a gene may truly play an important role in cancer has come
from a study in mice employing germline disruption of one allele
The classic hallmark of tumor suppressor genes is the loss of Hic1. This maneuver predisposes mice to an age- and gender-
of their function through genetic mutations in human cancer dependent spectrum of malignant tumors, suggesting tumor
(Hanahan and Weinberg, 2000). However, such functional dis- suppressor functions in vivo (Chen et al., 2003). Interestingly,
ruption has now also been associated with transcriptional inacti- as in human cancers, loss of function of the remaining wild-
vation of defined tumor suppressor genes in association with type Hic1 allele in cancers from the heterozygous mice appears
promoter hypermethylation (Jones and Baylin, 2002). In recent only in association with hypermethylation of one of the two
years, there has been a growing list of candidate tumor suppres- promoters for the gene, which is sufficient to inactivate it tran-
sor genes that appear to be modified only by such epigenetic scriptionally (Chen et al., 2003).
mechanisms, such as HIC1 (Chen et al., 2003; Wales et al., While the above mouse studies indicate a tumor suppressor
1995) and RASSF1A (Dammann et al., 2000). HIC1 encodes a role for epigenetically silenced Hic1, it remains to be further
zinc finger transcriptional factor that represses transcription resolved that loss of Hic1 function, and that for other epigenet-
both dependent and independent of class I histone deacetylases ically silenced genes, in association with promoter hypermethy-
lation, is a cause rather than a consequence of tumorigenesis.(Deltour et al., 1999, 2002). Hic1 is essential for mouse develop-
ment, and homozygous deletion of Hic1 results in embryonic This is especially so since cancer evolves with multiple genetic
and epigenetic alterations (Hanahan and Weinberg, 2000; Jonesand perinatal lethality (Carter et al., 2000). Evidence that such
S I G N I F I C A N C E
This paper addresses the fundamental question of whether, in cancer, genes altered solely through epigenetic gene silencing can
significantly influence tumor progression events driven by classic tumor suppressor genes altered through mutations. Using Hic1 and
p53 double heterozygous knockout mice, we show that the epigenetically silenced gene, Hic1, cooperates with the mutated tumor
suppressor gene, p53, in determining cancer progression and spectrum. The work provides experimental evidence that epigenetic
modification alone can serve as a “hit” in the tumorigenesis pathway, and suggests that human chromosome 17p13 is harboring
two tumor suppressors that could function individually or synergistically, each using different mechanisms for inactivation.
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and Baylin, 2002). It is thus critical to determine whether loss
of Hic1 function can play a significant role in the progression
of cancers in conjunction with defined genetic alterations of
powerful tumor suppressor genes. Toward these goals, we have
now crossed Hic1 heterozygous mice to mice carrying the dis-
ruption of p53, a classic and one of the most powerful and
frequently mutated tumor suppressor genes. HIC1 and p53 are
located on the same chromosome at positions 17p13.3 and
17p13.1, respectively, in humans. The deletion of these regions
on at least one chromosome is frequently observed in cancers,
including breast and ovarian carcinomas (Cornelis et al., 1994;
Konishi et al., 1998; Phillips et al., 1996; Saxena et al., 1992).
The intact copy for p53 is then frequently mutated, and that for
Hic1 is frequently hypermethylated (Chen et al., 2003; Fujii et
al., 1998; Narayan et al., 2003; Rathi et al., 2003).
In mice, both Hic1 and p53 are also closely located on
chromosome 11, with another tumor suppressor gene, Nf1,
residing in between them. It has been shown that disruption of
Nf1 cooperates with p53 disruption differently when deleted on
separate chromosomes (trans) versus on the same chromosome
(cis) (Cichowski et al., 1999; Vogel et al., 1999). Cis Nf1/p53/
mice have far more accelerated tumorigenesis than trans
Nf1/p53/ mice due to codeletion of the wild-type alleles for
each gene in tumors. Therefore, we reasoned that if genetic
codeletion of Hic1 with p53 would occur in the cis Hic1/p53/
mice, it might result in deletion of both wild-type copies of the
genes on the opposite chromosome. If loss of Hic1 function
were causal and critical for key steps in tumorigenesis, codele-
tion of Hic1 with p53 might produce far different tumor pheno-
types from those seen in p53/ or cis Nf1/p53/ mice. Cre-
ating genetic deletion rather than hypermethylation of the
wild-type allele of Hic1 in adult cancer might thus provide even
more insight into the true power of the tumor suppressor role
of this gene. Our results have borne out all of the above hypothe-
ses and well illustrate how an epigenetically silenced gene can
not only cooperate with genetically altered tumor suppressor
genes but also play a strong role in determining the course of
tumorigenesis.
Results and discussion
Phenotypes of trans double heterozygotes
We first generated trans double heterozygotes that carried
germline disruptions of Hic1 and p53 on separate chromo-
somes. In a 100-week study, as observed before (Chen et al.,
Figure 1. Phenotypes of trans Hic1/p53/ mice2003), Hic1/ cohort mice in their late life developed a gender-
A: Malignant tumor incidence. There were 100 trans Hic1/p53/ (trans-dependent spectrum of malignant tumors in which males devel-
DH), 54 p53/, and 24 Hic1/ mice. OSA, osteosarcoma; STSA, soft tissueoped predominantly carcinomas, while females developed only
sarcoma; LYM, lymphoma; CA, carcinoma.lymphomas and soft tissue sarcomas (Figure 1A and data not B: Incidence of osteosarcomas with age. For mice younger than 73 weeks,
shown). In contrast, trans Hic1/p53/ mice did not exhibit there were ten OSA in 38 trans-DH, and six in 26 p53/ mice. For mice 73
weeks and older, there were 25 OSA in 62 trans-DH and five in 28 p53/significant gender bias of malignant tumors due to the rapid
mice.occurrence of lymphomas and sarcomas in the p53/ back-
C: Incidence of mammary gland and ovarian tumors. There were 64 transground, and there was no acceleration of tumorigenesis for
Hic1/p53/, 24 p53/, and 14 Hic1/ females, and there were 5 mam-
trans Hic1/p53/ mice compared to p53/ mice (data not mary gland tumors and 7 ovarian tumors in the trans-DH, while there was
shown). However, trans Hic1/p53/ mice developed, in an only one ovarian tumor in p53/ mice.
D–G: Representative histology of an adenosquamous mammary tumorage-dependent manner, a higher incidence of osteosarco-
composed of nests and lobules of epithelial cells exhibiting glandular (D,mas than p53/ mice, while soft tissue sarcomas and lympho-
arrow, 100) and squamous differentiation (E, arrow, 400), and a typical
mas had similar incidence between the two groups (Figure osteosarcoma in the trans-DH mice demonstrating polygonal to spindle-
1A). Thirty-five osteosarcomas were identified in 100 trans shaped neoplastic cells producing bone (F, 200). Metastatic osteosarco-
mas from trans Hic1/p53/mice contained multiple, variably sized, promi-Hic1/p53/ mice (35%) compared to 11 osteosarcomas in
nent vascular spaces (telangiectatic pattern, G, arrows, 400).54 p53/ mice (20%, p  0.058). However, when age is taken
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into account, the incidence of osteosarcomas in the trans double
heterozygotes increased significantly (Figure 1B). Twenty-five
osteosarcomas occurred in 62 trans Hic1/p53/ mice (40%)
older than 73 weeks, whereas 5 in 28 p53/ mice (18%) devel-
oped this tumor for the same age range (p 0.036). In contrast,
both trans Hic1/p53/ and p53/ mice developed similar
incidence of osteosarcomas before 73 weeks (Figure 1B). The
osteosarcomas in the trans mice also had a higher metastasis
rate as described further later.
Importantly, we identified five mammary gland and seven
ovarian tumors in 64 trans Hic1/p53/ females (19%), versus
only a single ovarian hemangiosarcoma in p53/ mice, and
none of these tumors in Hic1/ mice (p  0.025, Figure 1C
and data not shown). The mammary tumors included four aden-
osquamous carcinomas and one myoepithelial tumor, which
was positive for smooth muscle actin (data not shown). The
adenosquamous carcinomas formed large masses composed
of glandular and squamous elements and invaded surrounding
tissues, but did not metastasize. Histologically, these carcino-
mas (Figures 1D and 1E) resembled the pilar mammary gland
tumors found in mice engineered for overactivity of the Wnt
pathway (Rosner et al., 2002), but appeared distinct from those
in mice with conditional Brca1 knockout in which diverse types
of carcinomas occur (Xu et al., 1999), and in mice lacking p53
and Brca2 or telomerase in which the acinar type of adenocarci-
noma predominates (Artandi et al., 2000; Jonkers et al., 2001).
The ovarian tumors of trans Hic1/p53/ mice included two
papillary cystadenomas, a choriocarcinoma, a carcinosarcoma,
a luteoma, and two hemangiosarcomas. Furthermore, trans
Hic1/p53/mice developed additional tumor types that were
not seen in either Hic1 or p53 heterozygotes alone, including a
metastatic neuroendocrine tumor, an adrenal pheochromocy-
toma, and a choriostoma in brain (data not shown).
Phenotypes of cis double heterozygotes
We then generated mice of the cis Hic1/p53/ setting. As
shown in Figure 2A, Hic1/ status did not accelerate tumorigen-
esis nor alter tumor spectrum in the p53/ background, and
thymic lymphoma continued to be dominant (data not shown).
However, cis double heterozygotes had a distinctly accelerated
tumorigenesis compared to cohort p53/ mice by tumor-free Figure 2. Phenotypes of cis Hic1/p53/ mice
survival analysis (p  0.011, Figure 2A). The cis Hic1/p53/
A: Kaplan-Meier analysis of tumor incidence. There were 20 p53/, 23
mice predominantly developed osteosarcomas, in sharp con- Hic1/p53/, 44 cis Hic1/p53/, 21 p53/, and 20 Hic1/ mice.
trast to the predominance of soft tissue sarcomas in p53/ B: Comparison of tumor incidence of cis Hic1/p53/ and cohort p53/
mice. There were 19 OSA and 5 STS in cis Hic1/p53/ mice compared tocohorts (Figure 2B). Nineteen osteosarcomas (43%) occurred
2 OSA and 10 STS in p53/ mice. LEU, leukemia; the other abbreviationsin 44 cis Hic1/p53/ mice, compared to 2 (10%) in 21 p53/
are the same as in Figure 1A.
mice (p  0.007). Osteosarcomas represented 55% of all 35 C: Comparison of tumor spectrum of cis Hic1/p53/ versus p53/ mice.
malignant tumors in cis Hic1/p53/ mice, whereas they were Thirty-five malignant tumors were identified in cis Hic1/p53/ mice and
sixteen in p53/ mice.13% in 16 malignant tumors in p53/ mice (p  0.005, Figure
2C). The tumor spectrum with predominance of soft tissue sar-
comas in our p53/ mice resembled that in cis Nf1/p53/
and their cohort p53/ mice (Cichowski et al., 1999; Vogel et
in the trans mice frequently metastasized to lung, liver, andal., 1999).
mesenchymal tissues. Most of these tumors showed classic
histological features of osteosarcomas (Figure 1F), but two hadMetastasis of osteosarcoma
telangiectatic patterns with large vessels formed in the distalWe found a higher incidence of metastatic osteosarcomas in
metastatic sites (Figure 1G), resembling the highly aggressiveboth trans and cis Hic1/p53/ mice than that in p53/ mice
osteosarcoma counterpart in humans (Spina et al., 1998). Simi-(Figure 3). In the trans mice, this difference was significant for
larly, in the cis mice, seven metastatic osteosarcomas occurredmice older than 73 weeks, as 12 metastatic osteosarcomas
in 44 mice compared to none in the 21 control p53/ mice (p(19%) occurred in 62 double heterozygotes compared to only
one (4%) in 28 p53/ mice (p 0.048, Figure 3A). These tumors 0.052, Figure 3B). All together, for 144 double heterozygous
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Figure 3. Incidence of metastatic osteosar-
comas
A: Metastatic osteosarcomas with age in trans
Hic1/p53/ versus p53/ mice. There were 7
metastatic osteosarcomas in 38 trans-DH mice
and 2 in 26 p53/ mice younger than 73 weeks.
There were 12 such tumors in 62 trans-DH mice
and 1 in 28 p53/ mice 73 weeks and older.
B: Metastatic osteosarcomas in cis Hic1/p53/
versus cohort p53/ mice. There were 7 meta-
static osteosarcomas in 44 cis-DH mice and none
in 21 cohort p53/ mice.
C: A combined incidence of metastatic osteo-
sarcomas in both trans and cis Hic1/p53/
mice compared to that in the combined cohort
of p53/ mice.
mice (trans plus cis), twenty-two (15%) developed metastatic type allele of p53 was observed for 27 out of 30 tumors in trans
osteosarcomas compared to three (4%) in 75 combined p53/ Hic1/p53/ mice (Figures 4B and 4F, and data not shown).
cohorts (p  0.013, Figure 3C). Interestingly, the size of the p53 deletion varied by tumor type
and did not always include the targeted Hic1 allele on the chro-
mosome. Thus, 7 out of 13 osteosarcomas retained the intactMechanisms for loss of function of Hic1 and p53
By Southern blot, we found that the wild-type allele of Hic1 targeted Hic1 allele, while in the rest it was deleted with wild-
type p53 (Figure 4A); in contrast, both the targeted Hic1 andwas retained in 29 of 30 various tumors analyzed from trans
Hic1/p53/ mice; for example, osteosarcomas and mam- wild-type p53 alleles were always deleted simultaneously in the
mammary adenosquamous carcinomas (Figures 4E and 4F).mary gland carcinomas (Figures 4A and 4E, and data not
shown). Only one ovarian tumor appeared to lose the wild-type We then analyzed promoter hypermethylation of the re-
maining wild-type Hic1 allele in tumors of trans Hic1/p53/Hic1 allele (data not shown). In contrast, deletion of the wild-
Figure 4. LOH analysis for Hic1 and p53
A–D: Southern blot analysis of osteosarcomas for
LOH status of Hic1 (A) and p53 (B) in tumors from
trans Hic1/p53/ mice, and loss of Hic1 (C)
and p53 (D) from cis Hic1/p53/ mice. In C
and D, preparations of normal bone from age-
matched mice were used as controls from
Hic1/ (n1) and cis Hic1/p53/ (n2) mice. In
B, tail DNA of trans Hic1/p53/ mice (t1 and
t2) was used as controls; for A, normal tissue con-
trol is illustrated in E, which was derived from the
same membrane as A. Tumor samples are ar-
ranged in the same order on gels for A and B,
and on gels for C and D.
E and F: Southern blot analysis of mammary
gland tumors for deletions of Hic1 (E) and p53
(F). Tumor 1 is a myoepithelial tumor, and the rest
are adenosquamous carcinomas. In E, an age-
matched normal mammary gland DNA (G) was
used as a control; in F, normal bone DNA (n2)
was used as a control. The numbers underneath
all gels are ratios of wild-type (wt) over targeted
alleles. The deletion of the wild-type allele was
considered to have occurred if the ratio was less
than 0.50 in order to distinguish it from hybridiza-
tion variation. In contrast, the deletion of the tar-
geted allele occurred if the ratio was higher than
2.0. For E, a small portion of the normal tissue
control was not completely digested by XbaI.
The ratio underneath lane G was calculated for
bands with complete digestion. If noncomplet-
ely digested bands were taken into consider-
ation, the ratio was 1.18. M, DNA ladder.
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Figure 5. Hic1 promoter hypermethylation anal-
ysis
A: HpaII-PCR assay (Chen et al., 2003) for mam-
mary gland tumors and normal, age-matched
mammary glands of wild-type (n1) and Hic1/
(n2) females. A strong PCR product generated
from input DNA digested with HpaII is seen only
for densely methylated Hic1 wild-type (wt) 1b
promoter in adenosquamous carcinomas (tu-
mors 2–5). Normal mammary glands had only
trace amounts of wt 1b promoter methylation
(n1 and n2) seen in aging mice.
B and C: HpaII-PCR assay for osteosarcomas from
trans Hic1/p53/ (B) and cis Hic1/p53/
mice (C); and normal bone controls from wild-
type (n1, n2 in C) and cis Hic1/p53/ (n3 in
C) mice. All tumor samples in A, B, and C were
arranged in the same order as they appeared
in Figures 4E, 4A, and 4C respectively.
D: HpaII-PCR assay for tumors in p53 heterozy-
gotes. OSA, osteosarcomas; STSA, soft tissue sar-
comas; LYM, lymphomas.
E: Summary of allele status of Hic1 and p53 in
osteosarcomas of trans versus cis double hetero-
zygotes. Unfilled triangle, wild-type p53; grid-filled
triangle, germline-disrupted p53; unfilled circle,
wild-type Hic1; grid-filled circle, germline-dis-
rupted Hic1; asterisk, hypermethylated Hic1; long
filled triangle, somatic chromosomal deletion in
tumors.
mice. We used a HpaII-PCR assay (Chen et al., 2003) previously ure 5B). Consistent with our previous findings (Chen et al., 2003),
we found that loss of Hic1 expression was associated withdesigned to distinguish methylation of the Hic1 downstream 1b
promoter in the wild-type allele versus the targeted allele that hypermethylation of the Hic1 promoter in both mammary gland
carcinomas and osteosarcomas examined, while abundant Hic1carries a targeting cassette for the replacement of Hic1 coding
exon 2 (Carter et al., 2000). All four mammary gland adenosqua- expression appeared in tumors without promoter hypermethyla-
tion (Figure 6). Interestingly, we also found that two out of fourmous carcinomas, but not the myoepithelial tumor, had dense
methylation of the wild-type Hic1 1b promoter similar to the osteosarcomas in control p53/mice had dense Hic1 1b hyper-
methylation (Figure 5D), but only one out of eleven soft tissuepattern seen for other carcinomas studied previously (Chen et
al., 2003) (Figure 5A). The osteosarcomas also had hypermethy- sarcomas and lymphomas had Hic1 promoter hypermethylation
(Figure 5D). These data indicate that loss of p53 function, alone,lation of Hic1 promoters. Eight out of 13 showed extensive wild-
type Hic1 1b promoter hypermethylation, and two also had predominantly contributes to soft tissue sarcomas and lympho-
mas in p53/ mice, but that concomitant loss of Hic1 functionhypermethylation extending to the upstream 1a promoter (Fig-
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erozygous mice. The exact molecular basis underling this
change is unknown; however, our data suggest that the simulta-
neous deletions of both wild-type genes in tumors from the cis
double heterozygotes occur because this is the most powerful
and efficient selection event for rapid tumorigenesis.
One possibility that must be considered for all of our above
findings in mice is that the large genomic deletions involving
p53 in the cis or trans Hic1/p53/ mice may involve other
genes on the chromosome. The first to be considered is Nf1
that lies between Hic1 and p53. However, in our cis disrupted
mice, one wild-type Nf1 allele is on the chromosome for which
the Hic1 and p53 genes are knocked out in the germline. No
somatic deletions occur for this chromosome in tumors (Figures
4C and 4D). Also, in the trans animals, at least one Nf1 allele
is intact on the chromosome that always retains wild-type Hic1
and germline-deleted p53. Therefore, in all of our mice, somatic
deletion occurred only on one chromosome (Figure 5E), and
Nf1 is always retained at least heterozygously. Any contribution
of Nf1 heterozygosity to the tumors observed is probably absent
or minimal for multiple reasons. First, Nf1 heterozygotes develop
Figure 6. Immunohistochemical analysis of Hic1 expression
frequent myeloid leukemia and pheochromocytoma (Jacks et
A: Strong Hic1 expression (brown stain) in a normal mammary duct sur-
al., 1994b) that are rare in our study, and the frequent tumorsrounded by epithelial cells (green arrow) and fat tissues, which are next to
we have observed, including osteosarcomas and mammarya mammary carcinoma.
B: Loss of Hic 1 expression in a mammary carcinoma with the Hic1 promoter gland and ovarian tumors, do not occur in Nf1 heterozygotes.
hypermethylation (nuclei highlighted by a purple stain, green arrow) com- Second, about 80% of tumors in cis Nf1/p53/ mice are soft
pared to the adjacent normal stromal tissues with Hic1 expression (brown tissue sarcomas (Cichowski et al., 1999; Vogel et al., 1999),
nuclei stain, black arrow). The inset illustrates an enlarged view of a tumor
but we have observed only 13% of such tumors in our cisglandular structure with negative Hic1 stain.
Hic1/p53/ mice with a similar mixed C57BL/6 and 129/SvC and D: Loss of Hic1 expression in osteosarcomas (purple nuclei) with Hic1
promoter hypermethylation (C), in contrast to strong expression (brown genetic background (Figure 2C). Third, we have observed 55%
nuclei) in those without hypermethylation (D). osteosarcomas in cis Hic1/p53/ mice, and these tumors
seldom develop in cis Nf1/p53/ mice. Finally, frequent
malignant peripheral nerve sheath tumors occur in cis Nf1/
p53/ mice, but do not occur in our cis Hic1/p53/ mice.
through promoter hypermethylation can be associated with de- All together, Hic1 has specific roles in tumor suppression in
velopment of osteosarcomas in these control p53/ mice. The cooperation with p53 in spite of the fact that Hic1 and Nf1 are
germline disruption of one allele of Hic1 in trans Hic1/p53/ located at very close loci.
mice appears to, then, increase the rate and virulence of osteo- Large chromosomal truncations induced by codeletion of
sarcomas and appearance of the breast neoplasms (Figure 1), Hic1 and p53 may also result in loss of other genes located on
by leaving only one Hic1 allele as a target for the hypermethyla- the same chromosome but distal from the Hic1-Nf1-p53 region.
tion. Together, our results suggest that epigenetic inactivation One such gene that could influence the tumor spectrum is Brca1.
of Hic1 cooperates with loss of p53 function to facilitate the While conditional knockout of both alleles of mouse Brca1 in
evolution of these tumor types. mammary glands results in spontaneous carcinomas (Xu et al.,
In contrast to the above findings for hypermethylation of 1999), heterozygous knockout of Brca1 in mice does not gener-
wild-type Hic1 in trans Hic1/p53/ mice, the wild-type Hic1 ate mammary gland tumors (Deng and Scott, 2000). Heterozy-
allele was deleted in all but one of 15 osteosarcomas and soft gous disruption of p53 can accelerate mammary gland carcino-
tissue sarcomas analyzed from cis Hic1/p53/ mice (Figure genesis in the Brca1 conditional setting (Xu et al., 1999);
4C and data not shown). While the wild-type p53 allele was however, nonconditional p53/Brca1/ double heterozygous
deleted in all tumors in cis double heterozygotes (Figure 4D), mice do not develop spontaneous mammary gland and ovarian
similar to that in the trans, the p53 deletion in 7 out of 13 tumors or have increased incidence of osteosarcomas (Cress-
osteosarcomas in the trans double heterozygotes did not in- man et al., 1999). The chromosomal loss induced by codeletion
clude the targeted Hic1 allele on the same chromosome, but of Hic1 and p53 on one chromosome in our study might span
both wild-type genes were codeleted in 11 out of 12 osteosarco- distal Brca1 as well; however, similar to Nf1 discussed above,
mas in the cis double heterozygotes (p  0.030). Interestingly, at least one allele of Brca1 will remain intact. The heterozygous
hypermethylation of the targeted 1b promoter continued to oc- status of Brca1 thus excludes any significant contribution of
cur (Figure 5C), suggesting that the methylation machinery in the Brca1 to the phenotypes observed in our studies.
tumors could still affect Hic1 promoters in the cis Hic1/p53/ Another gene that could possibly play a role in our findings
mice. The above data for different sizes of p53 deletion in the is Nf2, which is located near the centromere of chromosome
tumors from the trans versus cis double heterozygotes, summa- 11 (Figure 7A). Intriguingly, heterozygous disruption of Nf2 pre-
rized in Figure 5E, indicate that deletion of Hic1 is not merely disposes mice to a high frequency of metastatic osteosarcomas,
driven by deletion of p53. Rather, there is a sharp switch from and mice double heterozygous for p53 and Nf2, either in cis or
in trans, also exhibit further accelerated formation of osteosar-epigenetic to genetic inactivation of Hic1 in the cis double het-
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Figure 7. Mapping of chromosomal deletion in
tumors
A: Schematic illustration of the genes on mouse
chromosome 11 that are important for tumori-
genesis, with their meiotic map positions in centi-
morgan (cM) included in parentheses. Positions
for four polymorphism markers are also labeled.
B: PCR polymorphic analysis of allelic loss of cis
and trans tumors at 1.5, 2.0, 20, and 66 cM loci.
Only tumors with informative germline polymor-
phic difference are shown. For cis OSAs, loss of
the 129/SvJae allele occurs for OSA 6 at 1.5 cM
and OSA 5 at 2.0 cM markers; loss of one allele,
either 129/SvJae or C57BL/6, occurs for OSA 1 at
all four markers. In sharp contrast, no loss of any
markers occurs in seven trans OSAs. Two mam-
mary gland carcinomas, CA3 and CA4, but not
CA1, have lost distal markers. G, germline (from
tail DNA); T, tumor; B6, C57Bl/6 control; 129, 129/
SvJae control.
C: Southern blot analysis of Nf2 status in cis osteo-
sarcomas. Italic numbers underneath the gel are
ratios of Nf2 over the single copy, targeted p53
allele. The two vertical numbers under control
lanes n1 (Hic1/) and n2 (Hic1/p53/) are ra-
tios of Nf2 over the wild-type p53, with two copies
of p53 in lane n1 and one copy in lane n2. Loss
of one copy of Nf2 is expected to result in the
ratio of Nf2 over the targeted p53 to be about
0.11. All of the cis tumors appear to have this
ratio higher than 0.11, suggesting the retention
of at least one copy of Nf2.
In B and C, the tumor number designation is the
same as that appearing in Figure 4 for trans os-
teosarcomas, mammary gland tumors, and cis
osteosarcomas, respectively.
comas, in which Nf2 is homozygously deleted in nearly all such mas and mammary gland tumors, and found multiple tumors
with informative germline polymorphisms in both cis and transtumors (McClatchey et al., 1998). Given the phenotypic similarity
of Nf2 mice to our mice, we set out to map the size of chromo- osteosarcomas (Figure 7B). For tumors, given all of the preced-
ing data presented, we assumed that loss of any marker oc-somal deletion in tumors, aiming to reveal the potential chromo-
somal mechanism that leads to loss of heterozygosity (LOH) of curred on the chromosome carrying wild-type p53. Three inde-
pendent cis osteosarcomas, in addition to deletion of the p53Hic1 and to determine the status of Nf2.
We first analyzed a series of polymorphic loci spanning and Hic1 loci, all had loss of centromeric 129/SvJae markers
at 1.5 or 2.0 cM, while OSA1 has deletions of either the 129/chromosome 11 and identified four simple sequence length
polymorphism (SSLP) markers distributing at 1.5, 2.0, 20, and SvJae or C57BL/6 markers along the entire chromosome. These
data suggest loss of the entire chromosome 11 as a LOH mecha-66 cM along the chromosome (Figure 7A) that were able to
distinguish C57BL/6 from 129/SvJae strains. We analyzed nism for the remaining wild-type Hic1 and p53 alleles in cis
tumors, rather than mitotic recombination, in which centromericgermline and tumor pairs for polymorphisms for all osteosarco-
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markers would be retained, or interstitial deletion or gene con- (data not shown). These results suggest that Hic1 does not
cooperate with the INK4a locus. Rather, it is likely that loss ofversion, in which only a limited size of deletion would occur.
In contrast to the above data for the cis double heterozy- Hic1 function directly complements loss of p53 function for
maximal effects on tumor progression.gotes, no loss of four markers occurred in any of seven trans
osteosarcomas with informative germline polymorphisms (Fig-
ure 7B), including three osteosarcomas (#3, #8, and #11) that HIC1 promoter hypermethylation and p53 mutations
in human osteosarcomashad lost the targeted Hic1 allele due to p53 deletion (Figure
4A). Interestingly, we found that two epithelial tumors, namely Finally, given all of our findings in the mouse studies, and partic-
ularly those for osteosarcomas, we wondered whether collabo-mammary gland adenosquamous carcinomas CA 3 and 4 in
the trans double heterozygous mice, carried large chromosomal ration between loss of Hic1 and p53 function might be relevant
to development of cancer in humans. We thus extended ourdeletions indicating likely loss of the entire chromosome (Figure
7B). These results suggest that mechanisms of p53 LOH in trans study to human osteosarcomas by examining the relationship
of HIC1 promoter hypermethylation to p53 mutations in thismice are dependent upon tumor types: epithelial tumors tend
to have large chromosomal deletion likely involving the entire disease. Osteosarcomas are uncommon and aggressive tu-
mors, occurring mostly in children and young adults (Spina etchromosome similar to the type of loss for the wild-type Apc
allele in intestinal adenomas in ApcMin mice (Luongo et al., 1994). al., 1998). Somatic p53 mutations in human osteosarcomas
range from 19% to 38%, depending on exon regions examinedIn contrast, p53 LOH in the osteosarcomas from the trans double
heterozygous mice occurs, primarily as interstitial deletions, with and detection methods used (Gokgoz et al., 2001; Miller et al.,
1996; Overholtzer et al., 2003; Radig et al., 1996). The presencethe size less than 19 cM toward the centromere or 27 cM toward
the telomere. Altogether, our data indicate that in osteosarco- of p53 mutations correlates with high levels of genomic instabil-
ity in osteosarcomas (Overholtzer et al. 2003). Recently, hyper-mas from the cis double heterozygous mice, the additional tu-
mor initiation and/or progression pressure for simultaneous in- methylation of HIC1 has been found in 17% of pediatric osteo-
sarcomas (Rathi et al., 2003).activation of both wild-type Hic1 and p53 on the wild-type
chromosome selects for a LOH mechanism involving entire We analyzed HIC1 hypermethylation in 44 osteosarcomas
that had previously been analyzed for p53 mutations by single-chromosomal loss.
Within the spectrum of the above dynamics of chromosomal strand conformation polymorphism analysis (SSCP) and PCR/
ligase-detection reaction (PCR/LDR) (Gokgoz et al., 2001; Over-loss, including the loss of an entire chromosome containing
wild-type Hic1 and p53 in tumors from the cis Hic1/p53/ holtzer et al., 2003). We identified HIC1 hypermethylation in 8
out of 21 tumors (38%) with p53 mutations, but only in 2 of 23mice, one copy of Nf2 should remain intact on the targeted
allele. To further verify this, we analyzed osteosarcomas directly tumors (9%) without p53 mutations (p  0.020, Figure 8). In an
additional set of nine osteosarcomas in which missense p53for Nf2 status by using Southern blots. As shown in Figure 7C,
all tumors indeed retained at least one copy of Nf2. Osteosarco- mutations were screened by immunohistochemistry and verified
with p53 gene chip and sequencing in this study, we also foundmas 1, 5, and 6 appeared to lose one copy of Nf2, consistent
with the results of the polymorphism analyses presented above frequent HIC1 hypermethylation that occurred in 4 out of 8
tumors with p53 missense mutations, but not in the one without(Figure 7B). Retention of at least one copy of Nf2 in our cis
osteosarcomas is in contrast to homozygous deletion of Nf2 in (Figure 8C). Altogether, HIC1 hypermethylation occurred in 12
out of 29 osteosarcomas (41%) with p53 mutations comparedosteosarcomas from Nf2/ or Nf2/p53/ double heterozy-
gous mice, suggesting that different mechanisms contribute to to 2 out of 24 tumors (8%) without p53 mutations (p  0.007).
Therefore, of 14 tumors with HIC1 hypermethylation, 12 (86%)the development of osteosarcomas in our studies versus those
for the same type of tumors in the setting of targeted disruption occurred in those with p53 mutations. These results are consis-
tent with our findings in the above mouse study, and suggestof Nf2.
that loss of HIC1 function may complement p53 mutations in
the development of a subset of human osteosarcomas.Hic1 and INK4a locus
To explore whether Hic1 will cooperate with other tumor sup-
pressor genes that impact the p53 pathway, we crossed Hic1 Insight of HIC1 as a tumor suppressor gene and genetic
versus epigenetic inactivationheterozygotes to INK4a locus knockout mice. The INK4a locus
encodes two tumor suppressor genes, p16INK4a and p19ARF, Although it has long been speculated that other tumor suppres-
sor genes exist on human chromosome 17p13 in addition tothrough alternative codon usage. P16INK4a protein inhibits cyclin
D-dependent kinases, Cdk4 and Cdk6, and keeps pRb function- p53 (Cornelis et al., 1994; Konishi et al., 1998; Phillips et al.,
1996; Saxena et al., 1992), we demonstrate that HIC1 qualifiesally active for G1 cell cycle control, while p19ARF protein positively
regulates p53 function by binding to and sequestering Mdm2 as such a gene using mouse models. Hic1 and p53 can function
as tumor suppressors individually, or work synergistically, each(Sherr, 2001). Loss of the INK4a locus (Serrano et al., 1996) or
p19ARF alone (Kamijo et al., 1997) strongly predisposes mice to using different mechanisms for their loss of function. When
germline disruptions of both genes are placed on the samespontaneous soft tissue sarcomas and lymphomas, while loss
of p16INK4a alone has milder impact on formation of these tumors chromosome, the mice exhibit accelerated tumorigenesis ac-
companied by loss of the entire chromosome containing wild-(Krimpenfort et al., 2001; Sharpless et al., 2001). We found that
Hic1 heterozygous status did not accelerate tumor formation type copies of both genes. These phenotypic and molecular
features are strikingly similar among three sets of compoundor significantly alter tumor spectrum in homozygous or heterozy-
gous INK4a locus knockout mice, and both INK4a heterozygous knockouts on mouse chromosome 11, namely cis Hic1/
p53/, cis Nf1/p53/, and cis Nf2/p53/. Selection pres-and Hic1/INK4a double heterozygous mice developed predomi-
nantly soft tissue sarcomas and lymphomas in a 90-week study sure to inactivate two genes on the same chromosome in these
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Figure 8. HIC1 promoter hypermethylation anal-
ysis of human osteosarcomas
A and B: Examples of HpaII-PCR analysis of hu-
man osteosarcomas without p53 mutations (A)
and with p53 mutations (B).
C: Summary of p53 mutations and HIC1 hyper-
methylation data. The p53 mutation status of 44
osteosarcoma samples determined in previous
studies with SSCP and PCR/LDR is listed in the 2nd
and 5th columns, labeled SSCP; nine osteosarco-
mas screened with IHC and verified with Gene-
Chip are listed in the 8th column, labeled IHC.
Two osteosarcomas with wild-type p53 by SSCP
(number 1 and 5) had HDM2 amplification. The
numbers given for the tumors listed in the table
are not the same as those numbers shown for
example tumors in A and B. *, stop codon.
settings results in the loss of the entire chromosome (Cichowski gous mouse tumors is clearly nonrandom. In the default state,
Hic1 is epigenetically inactivated, probably as a result of localet al., 1999; Eden et al., 2003; McClatchey et al., 1998; Vogel
et al., 1999). The striking difference, and novel situation, for chromatin events. Thus, in the trans setting, changing the wild-
type Hic1 inactivation route to deletion would not provide addi-Hic1, as opposed to the studies for Nf1 or Nf2, is that such a cis
double heterozygous scenario converts the usual mechanism tional selection advantage for clonal expansion, since the nearby
p53 gene has already been knocked out by the targeting event.of epigenetic inactivation of this gene to one of chromosomal
deletion. In the cis setting, however, deletion of Hic1 would clearly have
more selection advantage than promoter hypermethylation, be-The switch of mechanism for Hic1 inactivation is intriguing.
One possibility is that the clonal evolution of the tumors would cause the deletion can simultaneously include the wild-type p53
on the same chromosome, whereas promoter hypermethylationsimply reflect the random collision of targeted allele events with
inactivation events on the opposite chromosome that would inactivates only Hic1. We cannot, obviously, fully rule out that
additional mechanisms could be at play between the cis andmost readily facilitate and select for tumorigenesis. The choice
for Hic1 inactivation between the trans and cis double heterozy- trans double heterozygotes. For example, the meiotic recombi-
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nation events necessary to derive the cis double heterozygotes can be genetically inactivated if the germline disruptions of this
gene and p53 are introduced into the same chromosome inmight have influence on this choice; however, the mice involved
in the study were not the mice harboring the original meiotic mice. This study not only provides further evidence that Hic1
recombination, but rather later offspring. Thus, the recombined is a tumor suppressor gene, but also shows that loss of function
allele has been through germline transmissions, and the wild- mediated predominantly by epigenetic events for given genes
type chromosome is universally derived from parents that have can effectively cooperate with genetic disruption of powerful
never undergone the original meiotic recombination process. tumor suppressor genes, such as p53, to drive tumorigenesis.
Another intriguing finding in our study is the promoter hyper-
Experimental proceduresmethylation on the targeted Hic1 allele, in both trans and cis
tumors. In both settings, there is no selection pressure to methyl-
Mouse colonies
ate the targeted allele, as Hic1 coding sequence has been We bred Hic1/ mice (on about 50% C57Bl/6 and 50% 129Sv/Jae) to
knocked out. There are at least three reasons why this may p53/ mice (on C57Bl/6, Jackson Lab) that carry the deletion of p53 exons
occur. First, the Hic1 promoter may be vulnerable for hyper- two to six (Jacks et al., 1994a) to generate trans Hic1/p53/ mice as
well as p53/ and Hic1/ cohorts. For study of cis double heterozygousmethylation. This is evident in that certain normal aging tissues
knockouts, we bred trans Hic1/p53/ mice with either wild-type or p53/can also bear a small degree of hypermethylation even in the
mice generated by mating p53/ mice. Six meiotic recombinantswild-type Hic1 allele, such as mammary glands (Figure 5A and
(Hic1/p53/ and cis Hic1/p53/) were identified at a frequency ofdata not shown). This is similar to the hypermethylation of other
1.2%. These six recombinants were then bred to p53/, p53/, and Hic1/
genes in tissues such as normal aging colon in humans (Issa mice to produce Hic1/ p53/, cis Hic1/ p53/, and their littermate
et al., 1994). Second, insertion of the targeting cassette carrying cohorts, p53/, p53/ and Hic1/ mice. Therefore, all mice in the trans
bacterial lacZ and neo sequences on the locus may promote and cis colonies had mixed C57Bl/6 and 129Sv background, with cis mice
having more C57Bl/6 background than trans. The use of mice in this studymethylation of the bacterial and adjacent cellular sequence. This
was approved by the Institutional Animal Care and Use Committee of Johnsphenomenon has been well documented in many transgenic
Hopkins University.studies (Engler et al., 1991; Hertz et al., 1999; Rose et al., 2000).
Third, hypermethylation of the targeted allele could be a second-
Mouse tumor analysis
ary event. In the clonal selection model for loss of Aprt function, We monitored mice closely for tumors or illness, and harvested and pro-
Rose et al. (2000) have found that hypermethylation of the Aprt cessed tumors as described previously (Chen et al., 2003). Skeletons of
promoter on the targeted allele carrying the neo expression mice with limb paralysis but without overt bone tumors were formalin fixed
and examined with radiography for possible small bone tumors. For Kaplan-cassette can occur in a passive way that is dependent upon
Meier analysis of tumor-free survival, mice with histologically confirmedthe promoter hypermethylation of the wild-type Aprt allele. Ho-
tumors or killed for severe illness were scored as death. Log-rank test wasmology-dependent trans allelic methylation or transvection then
used for calculating statistical significance. For measuring metastasis rate,may render hypermethylation of promoters on the targeted al-
we performed careful histological examination for osteosarcomas and other
lele. Transvection might thus provide a source for promoter tumors in all major organs of each mouse to compare with histology of the
hypermethylation of the targeted Hic1 allele in the trans tumors, primary tumor. Immunohistochemical staining of paraffin-embedded tissues
but could not apply directly to the cis tumors where the wild- was carried out as previously described (Chen et al., 2003).
type Hic1 is deleted.
Molecular analysis of mouse tumorsFinally, functional cooperation of HIC1 and p53 in tumor
Tumor DNA was extracted as described (Chen et al., 2003). For normal bonesuppression is interesting, as the HIC1 promoter contains a
controls, surgically normal femurs were removed and flushed with saline toconsensus p53 binding site (Wales et al., 1995), and overexpres-
remove bone marrow. The cancellous parts of femurs were pooled, crushed,
sion of p53 can transactivate silent endogenous HIC1 in cultured and then used for DNA extraction. For normal mammary gland controls,
human cancer cell lines (Guerardel et al., 2001; Wales et al., surgically normal whole mammary fat pads were dissected for DNA extrac-
1995). We therefore speculate that HIC1 might be involved in tion. Hic1 deletion and methylation status were analyzed as described (Chen
et al., 2003). Southern blot analysis of p53 was done as described (Jacksa certain feedback regulation for p53 in tumor suppression. One
et al., 1994a), except that genomic DNA was digested with StuI only so thatprevious example for the feedback regulation of p53 function
the p53 pseudogene was detected at a higher molecular weight, 3.6 kb.is MDM2. P53 can transactivate MDM2, whereas MDM2 binds
Quantitation of blot signals was performed using a PhosphorImager, andthe p53 N terminus, promotes ubiquitin-mediated degradation
after subtracting background, intensity of each band was used for calculating
of p53, and thus inhibits its function in controlling G1 cell cycle ratios of the wild-type over targeted allele.
arrest and apoptosis (Levine, 1997). Other tumor suppressor
genes can act through this pathway by neutralizing MDM2- Mapping chromosomal deletion
For PCR polymorphism analysis, we first verified primers (from Jackson Lab)mediated inhibition of p53; for example, the Nf2 gene product,
to be able to distinguish C57BL/6 versus 129/SvJae strains, and then appliedmerlin, promotes degradation of MDM2 and therefore stabilizes
them for analyzing tumor and tail DNA. For Southern blot analysis of Nf2,p53 (Kim et al., 2004). Interestingly, in our mouse studies de-
we PCR synthesized a short Nf2 probe that covers the unique sequence for
scribed above, Hic1 heterozygosity did not cooperate with the the PstI-EcoRI region around exon 2, which detects a 1.1 kb fragment of
Ink4a locus, in which p19Arf blocks Mdm2 interaction with p53, Nf2 in StuI-digested genomic DNA (McClatchey et al., 1997). The membrane
and two human osteosarcomas with MDM2 amplification did was simultaneously probed with p53 and Nf2 probes and analyzed as above.
not show HIC1 hypermethylation (Figure 6C), suggesting that
Human osteosarcoma analysisHIC1 may not act through the MDM2 pathway.
We analyzed a total of 53 human osteosarcoma samples for p53 mutationsIn summary, we have found that Hic1 plays a crucial role,
and Hic1 promoter hypermethylation. Forty-four of these human samplesby cooperating with p53, in controlling osteosarcoma and mam-
had been collected and analyzed previously for p53 mutations by SSCP and
mary gland carcinoma formation. Although loss of Hic1 function PCR/LDR (Gokgoz et al., 2001; Overholtzer et al., 2003), and nine additional
is most often achieved through an epigenetic mechanism during samples were collected at Memorial Sloan-Kettering Cancer Center using
a protocol approved by the MSKCC Institutional Review Board. These lattertumor development in humans and in our mouse models, Hic1
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for allele loss in breast tumors without p53 mutations. Cancer Res. 54,samples were initially screened for p53 missense mutations by immunohisto-
4200–4206.chemistry (IHC) with antibody DO7 (DAKO, Carpinteria, CA; 1:500; 0.2 g/ml)
as previously described (Lonardo et al., 1997). Cells with moderate to intense Cressman, V.L., Backlund, D.C., Hicks, E.M., Gowen, L.C., Godfrey, V., and
nuclear staining were scored positive, and samples containing more than Koller, B.H. (1999). Mammary tumor formation in p53- and BRCA1-deficient
20% IHC positive tumor cells were considered positive for potential p53 mice. Cell Growth Differ. 10, 1–10.
missense mutations. This cut-off percentage was chosen according to pre-
Dammann, R., Li, C., Yoon, J.H., Chin, P.L., Bates, S., and Pfeifer, G.P.viously established thresholds (Lonardo et al., 1997). The IHC positive sam-
(2000). Epigenetic inactivation of a RAS association domain family proteinples were then verified with p53 GeneChip analysis (Affymetrix, Santa Clara,
from the lung tumour suppressor locus 3p21.3. Nat. Genet. 25, 315–319.CA) on DNA extracted from frozen tissue. Mutations with GeneChip report
scores11 were considered genuine (Ahrendt et al., 1999; Wen et al., 2000; Deltour, S., Guerardel, C., and Leprince, D. (1999). Recruitment of SMRT/
Wikman et al., 2000). We confirmed those mutations that had only borderline N-CoR-mSin3A-HDAC-repressing complexes is not a general mecha-
GeneChip scores (namely, 12–15) by direct sequencing. The concordance nism for BTB/POZ transcriptional repressors: The case of HIC-1 and
of GeneChip and sequencing analysis has been previously demonstrated gammaFBP-B. Proc. Natl. Acad. Sci. USA 96, 14831–14836.
to be better than 80% (Ahrendt et al., 1999; Wen et al., 2000; Wikman et
Deltour, S., Pinte, S., Guerardel, C., Wasylyk, B., and Leprince, D. (2002).al., 2000). For analysis of HIC1 promoter hypermethylation, HpaII-PCR assay
The human candidate tumor suppressor gene HIC1 recruits CtBP throughwas performed with 35 cycle PCR using the same conditions as previously
a degenerate GLDLSKK motif. Mol. Cell. Biol. 22, 4890–4901.
described (Chen et al., 2003).
To ensure, for detection of p53 mutations, the concordance of IHC with Deng, C.X., and Scott, F. (2000). Role of the tumor suppressor gene Brca1
in genetic stability and mammary gland tumor formation. Oncogene 19,molecular assays for osteosarcomas, we found, in a separate study of 15
1059–1064.osteosarcomas that are not available for Hic1 methylation analysis, that only
one out of eight IHC negative osteosarcomas carried a p53 mutation as
Eden, A., Gaudet, F., Waghmare, A., and Jaenisch, R. (2003). Chromosomal
detected by SSCP and PCR/LDR. Also, of seven IHC positive osteosarco- instability and tumors promoted by DNA hypomethylation. Science 300, 455.
mas, five were indeed positive for p53 mutations by SSCP and/or PCR/LDR
Engler, P., Haasch, D., Pinkert, C.A., Doglio, L., Glymour, M., Brinster, R.,(M.O., unpublished data). Therefore, the overall concordance is similar to
and Storb, U. (1991). A strain-specific modifier on mouse chromosome 4that found for other types of tumors (Baas et al., 1994; Hsia et al., 2000;
controls the methylation of independent transgene loci. Cell 65, 939–947.Lonardo et al., 1997).
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